Table 2 Clinical characteristics of patients for the two cohorts
Main cohort (N=25): phase II clinical trial patients; DCE-MRI vs. IVIM-DWI | |
|---|---|
Disease | liver metastases from colorectal cancer |
Primary cancer | colorectal (all patients) |
Treatment | oral anti-angiogenic drug (Regorafenib) administered daily |
Sex [Female/Male] | 9/16 |
Age in years (mean ± SD; range) | 64.4 ± 10.7; 44 - 86 |
Lesion volume in mL (mean ± SD; range) | 45.8 ± 60.1; 2.2 - 265.1 |
Repeatability cohort (N=5): clinical patients; IVIM-DWI | |
Disease | liver metastases from gastrointestinal cancer |
Primary cancer | 3 colorectal, 1 stomach, 1 caecal |
Treatment | not relevant |
Sex [Female/Male] | 2/3 |
Age in years (mean ± SD, range) | 61.0 ± 11.6; 50 - 80 |
Lesion volume in mL (mean ± SD, range) | 91.9 ± 164.5; 4.1 - 385.6 |